GlassScriptPhysician profile
Evyan Jawad
NPI 1740443506
$2,123.19
in general payments reported to CMS, 2019-2025
28 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $10.10 · 2021: $97.22 · 2022: $232 · 2023: $668 · 2024: $326 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.03 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $232.46 | 2023-2025 | Xarelto, Uptravi |
| Merck Sharp & Dohme LLC | $222.50 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $207.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $183.95 | 2023-2025 | Eliquis |
| Cardiovascular Systems INC. | $150.50 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.14 | 2023-2025 | Jardiance |
| Teleflex LLC | $122.31 | 2022-2023 | Manta, Turnpike |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $101.82 | 2023-2025 | Lifevest |
| Abiomed | $97.05 | 2019-2022 | |
| Medtronic Vascular, INC. | $74.37 | 2019 | |
| Amgen INC. | $68.23 | 2024-2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $64.99 | 2023 | Atacand |
| Grifols USA, LLC | $50.95 | 2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $47.40 | 2024-2025 | Opsumit, Uptravi |
| Medtronic, INC. | $44.63 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $35.45 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.17 | 2025 | Glassia |
| Pfizer INC. | $35.12 | 2023 | |
| Philips North America LLC | $32.54 | 2025 | Vest Therapy Und |
| Baxter Healthcare | $31.07 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Endologix LLC | $23.59 | 2024 | Alto Abdominal Stent Graft System |
| Abbott Laboratories | $23.34 | 2019 | |
| Lilly USA, LLC | $21.80 | 2025 | Zepbound |
| Genentech USA, INC. | $21.11 | 2025 | Xolair |
| Daiichi Sankyo INC. | $19.96 | 2023 | Injectafer |
| Boston Scientific Corporation | $15.43 | 2021 | |
| Atricure, INC. | $13.38 | 2024 | |
| Biotronik INC. | $12.82 | 2023 | Orsiro Mission, Pk Papyrus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evyan Jawad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.